A few studies have attempted clinical trials using Type I IFN in COVID-19 patients where one reported an increased discharge rate and decreased mortality in patients [49], while another [50] noted that treatment using IFN-α2b with or without arbidol reduced the presence of virus in the upper respiratory tract and decreased levels of proinflammatory IL-6 and C-reactive protein (CRP). This evidence concerns the gene CRP and COVID-19.